undamentalytics Newsletter
Sign in

Immunome Inc. (IMNM) stock

Add to watchlist

Add holding +

NASDAQ: IMNM Nasdaq Biotechnology Next results ~November 5, 2026

E Fundamentals grade

Immunome Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Immunome Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.

Immunome Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 7 selling11 purchases and 28 sales by directors and officers, last 12 monthsInsider trades
  • Funds105 adding, 86 cuttingOf 40 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Immunome files

Where Immunome stands after its latest 10-Q

Immunome has little or no product revenue yet; it used $219m of cash in the twelve months to June 2026. That puts it 118 of 122 for growth among the biotechnology companies we cover. The diluted share count is up 41.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Our model value for Immunome is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Immunome Inc.'s trailing-twelve-month revenue fell 100.0% year on year, with a free-cash-flow margin of -5118.9%. Where it lags: revenue growth of -100.0% ranks 167 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -100.0% (-36.7pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Immunome Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Growth slowing. The growth rate is 36.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -5947.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 3953.6 points on a year ago.
  • Burning cash. Free cash flow was -5118.9% of revenue over the last 12 months.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.65 against an average estimate of -$0.50: missed by 28.8%
Share reaction
+9.0% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.60

Immunome's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+7.6%
  • 1 week+9.5%
  • 1 month-6.3%
  • This year-8.8%
  • 1 year+21.9%
  • 5 years-10.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
Operating margin
-5947.9%
Net margin
-5593.8%
EPS (TTM, diluted)
$-2.48

Growth

Revenue growth
−100.0%
Change in growth rate
−36.7 pts
Share count change
+41.4%

Cash

Free cash flow (TTM)
-$219M
FCF margin
-5118.9%
Stock pay % of revenue
695.9%

Earnings

Last results
August 11, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Insider trade
  4. Insider trade
  5. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Immunome Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Immunome Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.31 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.4 ~$1.4–$5.3 Left out: out of range vs price (0.07x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Immunome Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025Now
Share price$10.70$10.62$21.48$19.59
Market value$637m$623m$1.9bn$2.0bn
+ Net debt (− = net cash)−$99m−$143m−$653m−$218m
Enterprise value$538m$479m$1.2bn$1.8bn
Multiples
Price / sales 45.4x68.9xn/m—
Price / earnings ————
Price / free cash flow ————
EV / EBITDA ————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $133330 and EPS of −$0.60 (range −$0.71 to −$0.41) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.33 +4% $266670 −96%
Next −$2.46 −6% $50m +18804%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +9.6% on 90 days ago. In the last 30 days, 0 analysts raised Immunome Inc.'s forecast and 10 cut it.

Consensus EPS forecast Immunome Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.12 Current fiscal year, 60 days ago: −$2.31 Current fiscal year, 30 days ago: −$2.29 Current fiscal year, 7 days ago: −$2.29 Current fiscal year, Now: −$2.33 −$2.33 Next fiscal year, 90 days ago: −$2.12 Next fiscal year, 60 days ago: −$2.48 Next fiscal year, 30 days ago: −$2.43 Next fiscal year, 7 days ago: −$2.48 Next fiscal year, Now: −$2.46 −$2.46

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.12−$2.12
60 days ago −$2.31−$2.48
30 days ago −$2.29−$2.43
7 days ago −$2.29−$2.48
Now −$2.33−$2.46

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.50 −$0.65 −28.8%
Dec 2025 −$0.57 −$0.76 −32.8%
Sept 2025 −$0.54 −$0.65 −19.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 11, 2026

No numeric guidance in Immunome Inc.'s latest earnings release (filed August 11, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

17 analysts, Oct 2026
Buy1694%
Hold16%
Sell00%

Monthly trend

  1. Oct 202631317
  2. Sep 202631216
  3. Aug 202631114
  4. Jul 202631114

Counts of recommendations published by analysts covering Immunome Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
17.0%
of tradable shares
Days to cover
10.98
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
6.3%
of shares
Employees
247
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IMNM+34%−83%+384%−1%+102%−9%
Industry peers (median)−36%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IMNM25%25%58%50%67%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IMNM−71%−84%−33%−66%−53%−45%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 2, 2020: 95% from February 24, 2021 to December 30, 2022. Getting back needed a 1857% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$15.24 – $29.82
From 52-week high
−34.3%
vs 50-day average
−12.0%
vs 200-day average
−12.8%
Volatility (1 year)
62%
Beta vs S&P 500
1.60

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±6.8%
After a week
5 up, 7 down
typical move ±13.2%
After a month
7 up, 5 down
typical move ±12.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +9.0% −0.1% +7.3% −2.8%
May 12, 2026 −3.5% +0.4% −14.5% −20.2%
March 3, 2026 +1.4% −0.2% −1.6% +1.1%
November 6, 2025 −0.7% −1.0% +7.6% +27.9%
August 6, 2025 −9.0% +0.7% −7.7% −3.0%
May 12, 2025 +6.0% +4.0% +7.4% +27.2%
March 19, 2025 +3.6% +0.8% −15.2% −5.4%
January 29, 2025 +13.7% +0.1% +28.0% +1.7%
November 13, 2024 −10.8% −0.6% −25.3% +0.7%
August 12, 2024 +4.7% +1.7% +10.7% +11.9%
May 14, 2024 −5.2% +1.7% −12.6% +2.8%
March 28, 2024 −13.4% −0.2% −20.6% −45.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Immunome Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Immunome Inc.
$0 $5M $10M $15M FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY23 Q4: $14M Revenue (TTM), FY24 Q1: $12.7M Revenue (TTM), FY24 Q2: $10.8M Revenue (TTM), FY24 Q3: $10.1M Revenue (TTM), FY24 Q4: $9M Revenue (TTM), FY25 Q1: $10.9M Revenue (TTM), FY25 Q2: $12.6M Revenue (TTM), FY25 Q3: $9.7M Revenue (TTM), FY25 Q4: $6.9M Revenue (TTM), FY26 Q1: $4M Revenue (TTM), FY26 Q2: $0 $0

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $14M
FY24 Q1 $12.7M
FY24 Q2 $10.8M
FY24 Q3 $10.1M
FY24 Q4 $9M
FY25 Q1 $10.9M
FY25 Q2 $12.6M
FY25 Q3 $9.7M
FY25 Q4 $6.9M
FY26 Q1 $4M
FY26 Q2 $0
Revenue growth, TTM YoY Immunome Inc.
-100% -50% 0% 50% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY24 Q4: -35.5% Revenue growth, TTM YoY, FY25 Q1: -13.8% Revenue growth, TTM YoY, FY25 Q2: 16.7% Revenue growth, TTM YoY, FY25 Q3: -4.4% Revenue growth, TTM YoY, FY25 Q4: -23.2% Revenue growth, TTM YoY, FY26 Q1: -63.3% Revenue growth, TTM YoY, FY26 Q2: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q4 -35.5%
FY25 Q1 -13.8%
FY25 Q2 16.7%
FY25 Q3 -4.4%
FY25 Q4 -23.2%
FY26 Q1 -63.3%
FY26 Q2 -100.0%
Operating margin (TTM) Immunome Inc.
-6000% -4000% -2000% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY26 Q1 Operating margin (TTM), FY23 Q4: -781.4% Operating margin (TTM), FY24 Q1: -1871.5% Operating margin (TTM), FY24 Q2: -2518.5% Operating margin (TTM), FY24 Q3: -3134.4% Operating margin (TTM), FY24 Q4: -3382.4% Operating margin (TTM), FY25 Q1: -1994.3% Operating margin (TTM), FY25 Q2: -1784.1% Operating margin (TTM), FY25 Q3: -2419.9% Operating margin (TTM), FY25 Q4: -3228.8% Operating margin (TTM), FY26 Q1: -5947.9% -5947.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -781.4%
FY24 Q1 -1871.5%
FY24 Q2 -2518.5%
FY24 Q3 -3134.4%
FY24 Q4 -3382.4%
FY25 Q1 -1994.3%
FY25 Q2 -1784.1%
FY25 Q3 -2419.9%
FY25 Q4 -3228.8%
FY26 Q1 -5947.9%
FCF margin (TTM) Immunome Inc.
-6000% -4000% -2000% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY26 Q1 FCF margin (TTM), FY23 Q4: -59.9% FCF margin (TTM), FY24 Q1: -361.1% FCF margin (TTM), FY24 Q2: -607.7% FCF margin (TTM), FY24 Q3: -914.1% FCF margin (TTM), FY24 Q4: -1304.8% FCF margin (TTM), FY25 Q1: -1475.2% FCF margin (TTM), FY25 Q2: -1476.8% FCF margin (TTM), FY25 Q3: -1982.0% FCF margin (TTM), FY25 Q4: -2890.1% FCF margin (TTM), FY26 Q1: -5118.9% -5118.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -59.9%
FY24 Q1 -361.1%
FY24 Q2 -607.7%
FY24 Q3 -914.1%
FY24 Q4 -1304.8%
FY25 Q1 -1475.2%
FY25 Q2 -1476.8%
FY25 Q3 -1982.0%
FY25 Q4 -2890.1%
FY26 Q1 -5118.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 14 9 7 0
EBITDA −109 −304 −222 −268
Operating income −110 −306 −224 −270
Net income −107 −293 −212 −254
Diluted EPS −$1.79 −$5.00 −$2.43 −$2.48
Growth (year on year)
Revenue — −35.5% −23.2% −100.0%
Margins
EBITDA margin −778.1% <−999% <−999% —
Operating margin −781.4% <−999% <−999% —
Net margin −761.9% <−999% <−999% —
Free-cash-flow margin −59.9% <−999% <−999% —
Cash flow
Cash from operations −8 −111 −191 −209
Capital spending 1 7 10 10
Free cash flow −8 −118 −201 −219
Stock-based pay 6 16 26 31
Free cash flow after stock pay −15 −134 −226 −250
Balance sheet
Cash 99 143 653 218
Total debt 0 0 0 0
Net debt (negative = net cash) −99 −143 −653 −218
Diluted shares 60m 59m 87m 102m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $565m
Short-term assets $538mLonger-term assets $27m
What it owes, and who funded it · $565m
Short-term liabilities $36mLonger-term liabilities $5mShareholders' equity $525m
  • Short-term assets cover short-term liabilities $538m of assets due within a year against $36m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $538m short-term assets against $5m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Immunome Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+41.4%
year over year
R&D spending
4652.4%
of revenue

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -100.0% 12.6% 167 of 172
Change in growth rate Growth -36.7pp -0.1pp 139 of 172
Operating margin Profitability -5947.9% -189.4% 162 of 175
Net margin Profitability -5593.8% -157.3% 167 of 180
Free-cash-flow margin Cash generation -5118.9% -145.4% 164 of 176
Stock pay as % of revenue Cash generation 695.9% 19.2% 169 of 179
Change in share count Balance sheet 41.4% 7.9% 140 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$2.5B
Institutions reporting
201
Shares held vs prior quarter
▲ 1.2%
Positions opened / closed
29 / 27

Top buyers and sellers, Q2 2026: 105 institutions bought and 86 sold ; the biggest buyer was T. Rowe Price Investment Management, Inc (+3.3M shares) and the biggest seller Jefferies Financial Group Inc (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
T. Rowe Price Investment Management, Inc. $417M 19.7M 16.7% ▲ 20.2%
FMR LLC $360M 17.0M 14.4% ▲ 0.1%
Blackrock, Inc. $187M 8.8M 7.5% ▲ 7.8%
State Street Corp $116M 5.5M 4.7% ▲ 1.8%
Wellington Management Group LLP $110M 5.2M 4.4% ▲ 10.1%
Redmile Group, LLC $104M 4.9M 4.2% ▼ 11.6%
Primecap Management Co $97.1M 4.6M 3.9% ▼ 4.3%
Vanguard Capital Management LLC $96.4M 4.6M 3.9% ▲ 2.7%
Driehaus Capital Management LLC $92.1M 4.3M 3.7% ▲ 6.0%
Enavate Sciences Gp, LLC $76.6M 3.6M 3.1% 0.0%
Geode Capital Management, LLC $58.4M 2.8M 2.3% ▲ 7.6%
Morgan Stanley $51M 2.4M 2.0% ▼ 15.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Immunome Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $2.3M 11 trades by 3 insiders, last 12 months Insider sales History → $27.5M 28 trades by 7 insiders · 94% under pre-set plans
Net ▼ $25.2M net selling
Insider Date Trade Shares Price Value
Higgins Jack Chief Scientific Officer September 11, 2026 Sell pre-set plan 13,200 $25.32 $334,224
Barchas Isaac Director August 12, 2026 Sell pre-set plan 11,048 $27.25 $301,058
Barchas Isaac Director August 11, 2026 Sell pre-set plan 62,291 $26.23 $1.6M
Barchas Isaac Director August 10, 2026 Sell pre-set plan 10,125 $26.07 $263,959
Barchas Isaac Director August 7, 2026 Sell pre-set plan 15,248 $26.06 $397,363
Barchas Isaac Director August 6, 2026 Sell pre-set plan 20,840 $26.06 $543,090
Horn Kinney CHIEF BUSINESS OFFICER August 4, 2026 Sell pre-set plan 90,616 $25.09 $2.3M
Barchas Isaac Director July 7, 2026 Sell pre-set plan 16,906 $24.20 $409,125
Horn Kinney CHIEF BUSINESS OFFICER July 7, 2026 Sell pre-set plan 1,092 $25.00 $27,300
Barchas Isaac Director July 6, 2026 Sell pre-set plan 83,094 $24.11 $2M
Barchas Isaac Director July 2, 2026 Sell pre-set plan 24,335 $23.33 $567,736
Barchas Isaac Director July 2, 2026 Sell pre-set plan 75,665 $22.35 $1.7M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 3, 2026
  • November 6, 2025
  • August 6, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Immunome Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Immunome Inc. in brief

What does Immunome Inc. do?
Immunome Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Immunome Inc.'s stock ticker?
Immunome Inc. trades under the ticker IMNM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Immunome Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Immunome Inc. reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
What is Immunome Inc.'s free cash flow?
Immunome Inc.'s free-cash-flow margin is -5118.9% of revenue over the trailing twelve months, ranking 164 of the 176 biotechnology companies we cover.
Who are Immunome Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are T. Rowe Price Investment Management, Inc., FMR LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Immunome Inc.'s market cap?
On November 2, 2026, Immunome Inc.'s market capitalisation was about $2B and net debt of -$218M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Immunome Inc. stock?
Over the last 12 months, Immunome Inc.'s directors and officers reported 11 open-market purchases and 28 sales on Form 4. The insider trading page charts every trade.
When is Immunome Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Immunome Inc. announces its own schedule.